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Key question: Is it possible to blind patients and investigators to treatment allocation in 
randomised sham CPAP controlled cross-over trials? 
Bottom line: Patient blinding may be possible with lack of full disclosure but investigator 
blinding is unlikely to be achieved. 
Why read on? This is the first study to raise important practical, scientific and ethical issues 
for any non-implantable medical device-based crossover trials where the maintenance of 
blinding depends on deliberately withholding full disclosure of the sham device.   
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Abstract 
Introduction: 
Performing rigorously designed clinical trials in device-based treatments  is challenging. 
Continuous positive airway pressure (CPAP) is the most effective device-based treatment for 
obstructive sleep apnoea (OSA).  We performed a randomised cross-over trial of CPAP 
versus placebo therapy, and did not disclose the presence of placebo. We assessed rates of 
staff unblinding, the likelihood of patient unblinding and obtained patient perceptions on lack 
of full disclosure. 
Methods 
All patients (n=30) underwent a semi-structured exit interview. Prior to full disclosure 
patients were asked questions to ascertain whether they suspected one therapy was 
ineffective. The use of placebo was then disclosed and additional questions were 
administered to indicate the likelihood of unblinding had full disclosure occurred during 
consent. Staff unblinding was determined by means of a questionnaire that was completed 
after each patient encounter. 
Results 
Whilst the lack of full disclosure prevented patient unblinding during the trial, patients 
revealed a clear preference for active CPAP. After disclosing the presence of placebo, 73% 
(n=22) felt they would have been unblinded had they known at the start of the trial. Only one 
patient described unease about the lack of full disclosure. Staff thought they were unblinded 
in 6% (n=16/282) of encounters. They correctly identified the treatment device in 69% of 
cases (n=11/16, p<0.001).  
Conclusion 
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Successful patient blinding was achieved, however, this was probably reliant on the lack of 
full disclosure. Staff unblinding occurred and highlights the difficulty with investigator 
blinding in device-based trials. Ethical challenges in this type of study are likely to 
compromise research feasibility. 
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Introduction 
In trials using pharmacotherapy, the use of an inert tablet is usually an appropriate control for 
placebo effects when used in conjunction with blinding of both patients and investigators. 
However, under the usual conditions of full disclosure, blinding of the patient is more 
challenging when using a non-pharmacological treatment such as a non-implantable medical 
device. The proportion of new treatments that are device based is increasing relative to drugs 
and other modalities. There is also concern about the differential standards for efficacy and 
safety applied to drugs and devices even when used to treat the same conditions. This has 
resulted in greater scrutiny of the evidence base for the effectiveness and safety of devices 
with the resultant need to design and encompass matching placebo devices in randomised 
controlled trials. However when devices have clear and immediate physical effects, it 
becomes challenging to successfully blind both participants and investigators under 
conditions where full disclosure is mandatory. 
 
One example of a non-implantable medical device is continuous positive airway pressure 
(CPAP) which is the standard treatment for obstructive sleep apnoea syndrome (OSA). It acts 
as a pneumatic splint of the upper airway during sleep by delivering air pressure from a pump 
to a mask worn on the face.  
 
A sham form of a CPAP device can be used as a placebo comparison for active CPAP. An 
active CPAP device ordinarily delivers pressures anywhere between 4 cm H20 and 20 cm 
H20. In a sham CPAP device, the exhalation port of the CPAP mask is increased in size, and 
a resistor is added between the pump and the tubing. In this way a pressure of less than 1 cm 
H20 is delivered to the mask whilst maintaining the same appearance and noise of an active 
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CPAP machine [1]. However, because air pressure is the mechanism of action, sham devices 
feel different due to a markedly lower mask air pressure compared to the therapeutic device. 
 
In chronic conditions such as OSA, randomised cross-over trials offer an efficient way to test 
interventions because of their relative statistical efficiency.  Patients are exposed to both 
sham and active CPAP interventions to compare device effectiveness within patients. 
However, this approach has raised concerns due to the difficulty of preserving blinding. If 
patients were told in advance (full disclosure) that one treatment was inert it would unblind 
the trial because patients could immediately tell which treatment had the lower pressure. One 
authors' (NM) experience from a previous sham CPAP cross-over trial was that patients 
immediately noticed the pressure differences after cross-over. Though they were asked not to 
discuss this with study personnel, they would often mention their experience of pressure 
change thereby inadvertently unblinding study personnel [2]. Several research groups that 
have recently conducted cross-over trials have made it clear in their manuscripts that they did 
not fully disclose to patients that they would receive ineffective (placebo) treatment [2-7]. 
This is due to concern that the resultant unblinding would render the trial scientifically 
uninterpretable, a concern first raised by Karlawish and Pack more than a decade ago [8]. 
However, withholding information conflicts with the concept of true informed consent [9]. A 
summary of disclosure patterns of published cross-over trials using sham CPAP is presented 
in Table 1. 
 
Despite these concerns, no studies to date have attempted to evaluate the success of blinding 
in randomised cross-over trials with sham CPAP. We conducted a placebo controlled cross-
over trial of CPAP where the existence of a placebo was not disclosed [6]. Using data from 
patient interview questions and from staff questionnaires during the trial, we sought to 
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determine (1) whether staff unblinding occurred, (2) whether patients thought they would 
have been unblinded had they known there would have been a placebo used in the trial and 
(3) patient perceptions on lack of full disclosure. 
 
Methods 
This is an auxiliary study of a published randomised cross-over trial comparing the effects of 
two months of CPAP to sham-CPAP on lipid metabolism in patients with moderate to severe 
OSA (apnoea-hypopnoea index ≥ 25/h sleep) [6]. The active and placebo CPAP devices 
(Remstar Auto; Philips Respironics, Murrysville, PA) were identical.  All other details 
regarding the study protocol may be found in the original report [6].  
The patient information sheet disclosed that patients would be using two CPAP machines that 
“will deliver pressure in a different way.” They were also told that one of the aims of the 
study was to determine “whether the way in which a CPAP machine delivers pressure is 
important in determining which machine you prefer to use.”  
Our local ethics committee was concerned about the lack of full disclosure and its effects on 
informed consent. However they also recognised the additional scientific problem that would 
be introduced by the trial becoming unblinded.  They agreed to approve the study, inclusive 
of withholding knowledge of the placebo device from patients, provided further investigation 
was performed to assess the impact of this withheld knowledge. Full disclosure was made at 
an exit interview with each patient before study discharge. In this interview, the reasoning for 
not fully disclosing the nature of the placebo device during the consenting process was 
explained.  
Final approval was sought from the Ethics committee (RPAH Zone) of the Sydney South 
West Area Health Service with study protocol number X05-0128. 
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Patient Exit interview  
Patients underwent a semi-structured exit interview at the time of completion or withdrawal 
from the study. All interviews were undertaken by the same investigator (NM) who remained 
nominally blinded to treatment allocation. Appendix A lists the scripted prompts and 
questions that were used by the interviewer with patients. Patients were initially asked 
numerous questions about their treatment experience/preferences. This was designed to elicit 
from the patient whether they suspected the existence of a placebo or non-efficacious 
treatment. Subsequently, an unblinded investigator (AD) took over the interview and 
debriefed the patients on the true nature of the study.  They  asked the patients 1) whether 
they felt they would have been unblinded if there had been full disclosure at the start of the 
study and 2) how they felt about not having been told that there was a placebo treatment used 
in the trial. Patients were asked what their bed-partners thought about the relative 
performance of each machine.   
 
Staff questionnaires  
Staff members were asked to complete the questionnaires after any type of encounter with the 
patient to determine whether they had been unblinded. Encounters included events such as 
venepuncture. The questionnaires were not completed after every single patient encounter as 
we had intended, as study personnel were often busy. The exact denominator, or number of 
staff-patient encounters, is unknown. If staff thought they were definitely unblinded, they 
were re-assigned so as to no longer have contact with the patient. 
 
Statistical analysis 
We used descriptive statistics, frequencies and percentages to describe our data. Chi Squared 
tests were used to test whether staff treatment allocation guesses were statistically correct 
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more often than 50% of the time. Mixed model analysis of variance was used (SAS v9.3) to 
test whether adherence rates differed between treatments and whether the order in which 
treatment was received affected adherence. Patient numbers were used as random effects and 
treatment, order and order by treatment interaction were fixed effects.  
 
Results 
In the original study, 38 patients were randomised and 29 completed the trial. Thirty-four 
patients started treatment but 3 withdrew almost immediately after initiating treatment. Staff 
questionnaires were obtained for the remaining 31 patients. Of these, 30 patients experienced 
both treatment arms and subsequently underwent the exit interview. One patient withdrew 
prior to completion of the second arm. No patients suspected the presence of a placebo during 
the trial. 
 
Patient Exit interview  
The patient perceptions of the two treatment arms are described in Table 2. Before being told 
that there was a placebo, the majority of patients identified the treatment arm with active 
CPAP as the preferred treatment, felt that it was better for their sleep, and preferred to use it 
in the long-term.  More patients thought their bed-partner would report that CPAP was more 
effective than placebo.   
 
After telling patients that there was a placebo, 73% (n=22, p=0.02) stated they felt they 
would have been able to determine which device was the placebo during the trial if full 
disclosure had occurred during the consenting process.  
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Only one patient stated that he felt slightly uncomfortable that full disclosure did not occur. 
All other patients reported that they understood why full disclosure had not occurred and that 
withholding this information was warranted. The interviewer also noted that very few 
patients remembered the contents of the informed consent documents they had signed and 
many had not retained these even though the trial was less than 6 months in duration. Some 
patients could not recall that there had been such a document. 
 
Staff questionnaires  
Staff questionnaires were completed for 31 patients. There were 282 staff-patient encounters 
documented. The number of staff encounters recorded per patient averaged 9 (SD 3, range 3-
15 per patient). Figure 1 illustrates the results of the staff questionnaires. 
 
Staff thought they were definitely unblinded in 6% (n=16/282) of recorded encounters and 
then mostly correctly identified the treatment (n=11/16, 69%, p<0.01). Staff thought they 
might have been unblinded in 22% (n= 61/282) of recorded encounters and they typically 
guessed correctly (n = 44/61, 72%, p<0.01). Of the 55 correct guesses/unblinding episodes, 
21 occurred in the first arm and 34 occurred in the second arm (p=0.11). 
 
Adherence  
Adherence was compared in those that started with active CPAP then crossed-over to sham 
CPAP, and vice versa (Table 3). CPAP adherence was highest in those that started with 
active CPAP and reduced significantly on commencing sham CPAP (5.6 vs. 3.5 hrs). In those 
that started with sham CPAP, adherence was low and remained low after commencing active 
CPAP (3.3 hrs vs. 3.2 hrs). 
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Discussion 
In this study, we sought to determine whether staff unblinding occurred in our sham CPAP 
cross-over trial. We also assessed the likelihood of patient unblinding had full disclosure 
occurred during the consenting process. We purposefully did not disclose the presence of a 
placebo in an effort to preserve blinding. Informing patients that the study aimed at testing 
“two different deliveries of pressure” rather than telling them that one treatment would be 
ineffective meant that patients should not have been able to have pre-determined perceptions 
of reduced benefit in either arm. Our results demonstrate that the vast majority (72%) of 
patients felt that they would have been able to identify the placebo treatment had they been 
informed at the start of the trial.  Prior to unblinding the patient, although no patient 
suspected that sham CPAP was used when directly prompted, the majority of patients were 
able to identify active CPAP as the more effective treatment. Examination of the staff-patient 
encounters reveals that unblinding occurs amongst staff. When staff members thought that 
they had been unblinded they were usually correct. Any degree of unblinding is undesirable 
and this study highlights the practical difficulties in preserving double blinding in a sham 
CPAP cross-over trial. We believe that staff blinding would be equally as problematic in 
parallel studies of sham CPAP.  
 
We found that adherence was influenced by type of treatment and by order of treatment. 
Firstly, adherence was lower on sham CPAP regardless of order of administration. In our 
trial, this was to be expected given the clear differences in patient preferences. However, 
those that commenced on sham CPAP first followed by active CPAP continued to have lower 
adherence, potentially due to their discouraging initial experience. This may imply that 
adherence is predictably affected by order of treatment interaction, also noted by other 
investigators [4, 10]. This highlights a shortcoming of cross-over trials. 
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Amongst the cross-over studies that did not disclose the presence of placebo, all but one 
study demonstrated a clear discrepancy between adherence rates in each arm, with lower rates 
in the sham CPAP arm [2-7]. The only study that showed equivalent rates of adherence 
between arms was a study performed in patients with mild OSA[2]. These patients had no 
clear preference for active CPAP presumably due to milder symptoms and reduced 
symptomatic benefit. Overall, in these studies where there was lack of full disclosure there 
was  lower use of sham CPAP devices. 
 
In contrast to the majority of cross-over trials, Weinstock et al [10] was the only group that 
we are aware of that clearly disclosed the existence of a placebo device at the time of consent 
(Susan Redline, personal communication). This study does not appear to have had significant 
issues with drop-outs, or dismal compliance on the sham arm as we may have predicted. 
However, they did find significantly lower adherence in the sham arm, particularly if it was 
provided on the second arm. One interpretation of this apparent success may be that patients 
did not remember the contents of the informed consent documents.   Additionally, it is 
difficult to make conclusions about the effect of full disclosure based on only one study.  
 
Interestingly, patients did not object to the lack of full disclosure when it was revealed to 
them. It may be because such a high proportion felt that their behaviour would have been 
influenced by this knowledge.  From our interviews it appears that informed consent 
documents were not valued by patients. They often did not remember what was in them, or 
that they existed. They often did not retain their provided copies. This suggests that these 
documents may not be serving their intended function. Even though our study had not 
intended to investigate patient perceptions of informed consent documents in clinical trials, it 
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was apparent through the interviews that patients in our trial derived very little if any value 
from them.  
 
Limitations include that we were unable to capture every single staff-patient encounter as 
they were numerous and the task relied on staff completion on every encounter. This might 
have led to preferential completion of the questionnaire after unblinding events. As such, the 
data might reflect spontaneous adverse event reporting data where unblinding events are 
more likely to be reported. In addition, after the exit interview and after full disclosure, we 
did not repeat the interview questions in Table 2 to verify that the -73% of patients who 
thought they could identify the active treatment actually could. A further limitation was that 
we never ascertained from the patients exposed to sham CPAP last, whether full disclosure 
would have resulted in them being less inclined to use it. This information would be 
important for ethics committees when considering future trials. 
 
The proportion of device-based treatment is on the rise. Rigorous research in this area differs 
to pharmacologic agents and is challenging with practical difficulties. Investigator blinding is 
difficult if not impossible to achieve both in parallel and cross-over design trials. We have 
found that with the use of sham CPAP in a cross-over trial, the only solution to maintaining 
patient blinding and scientific integrity is to abstain from disclosing to patients the existence 
of a placebo. This in turn creates an ethical dilemma and is a challenge that warrants further 
attention and discussion.  
  
Page 15 of 21
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Page 16 of 20 
 
*personal communications with Grace Robinson and John Stradling 
#personal communications with Miguel Arias 
$personal communications with Susan Redline 
^personal communications with Anne Jones and Renata Riha 
 
Table 1. Summary of level of disclosure in published randomised cross-over trials using sham 
CPAP 
Author Full placebo 
disclosure 
Available information on level of disclosure 
Marshall 2005[2] No Manuscript states: "patients were informed that the 
study was ‘testing two different pressures of humidified 
CPAP'" 
Robinson 2006 [3] No Personal communication: patients were not told that one 
pressure was completely ineffective* 
Coughlin 2007[4] No Manuscript states: "Low pressure alternative that might 
provide some symptomatic benefit" 
Cross 2008[5] No Personal communication: similar protocol as per Jones 
paper below^ 
Phillips 
2011,[6] 
Phillips 
2012, [11] 
McEwen 
2012[12] 
Same 
trial 
No Patients were informed that they would be receiving two 
different pressures 
Jones 2013[7] No Patient information sheet: “You will receive two 
different types of CPAP. CPAP machines can be set to 
provide air at different pressures. You will receive one 
such pressure for three months, and a different pressure 
for the second three month period.” 
 
Arias 2006[13] Unclear Manuscript states: "patients were not informed of the 
type of therapy they were receiving." Personal 
communication confirmed patients were blinded. 
Alonso-Fernandez 
2006[14] 
Unclear Manuscript states:“…they were not informed of the type 
of therapy there were receiving” 
 
Arias 2008[15] Unclear Manuscript states: “they were not informed of the type 
of therapy there were receiving.” Personal 
communication confirmed patients were blinded. 
Alonso-Fernandez 
2009[16] 
Unclear Manuscript states: “No information about the type of 
therapy they were receiving was given” 
Weinstock 2012 [10] Yes Full disclosure was made to patients regarding the use 
and implications of sham CPAP $ 
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Table 2. Patient perceptions of the two treatment arms, active CPAP and sham CPAP, at 
the exit interview (n=30). Active CPAP was consistently identified as the preferred treatment 
before disclosure of the presence of a placebo had occurred. 
True 
CPAP 
(%) 
Sham  
CPAP 
(%) 
Unsure/ 
Equal 
(%) 
Don't know/ 
no bed partner 
(%) 
Overall preference 19 (63) 8 (27) 3 (10) - 
Led to better sleep 19 (64) 7 (23) 4 (13) - 
Preferred for long term use 20 (67) 8 (27) 2 (6) - 
Presumed bed partner preference 12 (40) 5 (17) 8 (27) 5 (17) 
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Table 3. CPAP adherence rates in each arm before and after cross-over.  
                                                                                                                         
Order of cross-over 
  
Adherence (Hours per 
night) 
1st arm (95% CI) 
Adherence (Hours per 
night) 
2nd arm (95% CI) 
Active CPAP then sham 
CPAP 
5.6  (4.4 - 6.8)** 3.5 (2.4 - 4.7) 
  
Sham CPAP then active 
CPAP 
  
3.3 (2.1 - 4.4) 3.2 (2.0 - 4.3) 
**p<0.01 for comparisons with every other cell. CPAP adherence is higher in the first arm 
than all other combinations. None of the other 3 cells are different from one another. This 
effect drove the difference in adherence seen in the trial overall between active and sham 
CPAP (1 hour 95% CI 0.2, 1.7, p=0.01) and the overall p-value for the interaction between 
treatment and the order in which it was received was <0.01. 
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Figure 1. Staff perceptions on patient treatment assignment after each staff-patient 
encounter.  
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